Marcel van der Brug

Company: AcuraStem Inc.

Job title: Chief Scientific Officer

Seminars:

Embracing Heterogeneity in ALS to Develop Diverse In Vitro Models that can Support Development of Targeted Therapeutics 11:00 am

ALS patients present with significant heterogeneity in disease features, that may share related, common mechanisms. Most ALS disease models focus on rare forms of the disease and are not genetically representative of >80% of patients with sporadic ALS. Developing and selecting drug candidates in diverse patient cell lines is standard practice in oncology therapeutic discovery.…Read more

day: Conference Day One Track A